Ken Griffin Pacific Biosciences Of California, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$1.36 - $3.65 $57,664 - $154,760	42,400 Added 40.27%	147,700 $202,000
Q1 2024 May 15, 2024	SELL	$3.52 - $9.59 $142,560 - $388,395	-40,500 Reduced 27.78%	105,300 $394,000
Q4 2023 Feb 14, 2024	SELL	$5.97 - $10.36 $89,550 - $155,400	-15,000 Reduced 9.33%	145,800 $1.43 Million
Q3 2023 Nov 14, 2023	SELL	$8.23 - $13.93 $575,277 - $973,707	-69,900 Reduced 30.3%	160,800 $1.34 Million
Q2 2023 Aug 14, 2023	SELL	$9.97 - $14.05 $1.26 Million - $1.78 Million	-126,800 Reduced 35.47%	230,700 $3.07 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $12.02 $763,828 - $1.16 Million	96,200 Added 36.82%	357,500 $4.14 Million
Q4 2022 Feb 14, 2023	BUY	$5.67 - $11.2 $1.11 Million - $2.2 Million	196,000 Added 300.15%	261,300 $2.14 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $8.57 $3,537 - $7,713	-900 Reduced 1.36%	65,300 $379,000

252

233M

971K

965K

Ticker PACB
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 224,840,992
Market Cap $564M
Description
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits design...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.